Eisai Inc. presented new data on FYCOMPA (perampanel) CIII at the American Epilepsy Society Annual Meeting in New Orleans which included analyses of convulsive seizure freedom rates in adult and pediatric epilepsy patients.
More than 50 scientific posters on FYCOMPA were presented by both Eisai and independent investigators, underscoring a collective commitment to advancing research in epilepsy care.
Of note, Eisai presented three post-hoc analyses evaluating the potential of FYCOMPA to help patients experience long-term, sustained convulsive seizure freedom, as well as data that supported the recent U.S. Food and Drug Administration (FDA) approval of FYCOMPA for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures. Additional data included all-cause and epilepsy-related hospitalizations with use of FYCOMPA compared to lacosamide.
‘These long-term seizure freedom data showed about 53% of patients with secondarily generalized seizures experienced convulsive seizure freedom at 2 years and close to 35% at 3 years,’ said Trevor Resnick, MD, Pediatric Neurologist at Nicklaus Children’s Hospital. ‘These results are very encouraging for patients who are affected by uncontrolled convulsive seizures and for whom seizure freedom remains an important treatment goal.’
FYCOMPA was initially approved for adjunctive use in POS in patients 12 years and older in 2012 and was later approved as adjunctive therapy for PGTC seizures in patients with epilepsy 12 years of age and older, and then as monotherapy for POS with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In September 2018, FYCOMPA was approved for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of POS with or without secondarily generalized seizures.
‘The broad scope of FYCOMPA data being presented highlights how FYCOMPA may help both children and adults on their journey toward the goal of seizure freedom,’ said Ivan Cheung, Chairman and CEO, Eisai Inc. ‘These data encourage us to continue the important work of conducting research that leads to improved clinical outcomes for these patients.’
To date, FYCOMPA is approved in 55 countries and has been used to treat more than 200,000 patients worldwide across all indications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.